Minimal Residual Disease Predicts Outcome in Follicular Lymphoma

Achieving undetectable MRD significantly increased progression-free and overall survival, especially for patients with early MRD response to induction therapy.

Achievement of minimal residual disease (MRD) negativity in peripheral blood and bone marrow correlates with improved outcomes in patients with B-cell non-Hodgkin lymphoma. These investigators evaluated the prognostic value of MRD status in patients with advanced follicular lymphoma undergoing immunochemotherapy in the industry-sponsored, multicenter, phase 3 GALLIUM trial (NEJM JW Oncol Hematol Oct 12 2017 and N Engl J Med 2017; 377:1331).

Previously untreated patients were randomized to induction with rituximab or obinutuzumab plus chemotherapy, followed by maintenance with the assigned antibody for 2 years. MRD was assessed by nested and quantitative PCR for clonal immunoglobulin gene rearrangement and the t(14;18) breakpoint; positive MR…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Minimal Residual Disease Predicts Outcome in Follicular Lymphoma

Topics

Reviewing Author